Editorial Feature:

The Art of Drug Choice

Wet AMD and the Latest Data

Editorially Independent content supported with advertising by Novartis and Alcon.

In this Feature

Management of IOI After Anti-VEGF Therapy in a 12-year Wet AMD Patient

Arshad M. Khanani, MD, MA

Switching Agents Multiple Times in a Long-term Wet AMD Patient

Lejla Vajzovic, MD

Extending Treatment Intervals in a 90-Year-Old Wet AMD Patient

Joseph M. Coney, MD

Increasing Treatment Intervals in Wet AMD

Arshad M. Khanani, MD

A Breakthrough After Monthly Wet AMD Therapy

Nikolas J.S. London, MD

Navigating Treatment Burden in Wet AMD

Christina Weng, MD, MBA

Outside-the-Box Therapy for Wet AMD

Christopher G. Fuller, MD

The Value of Treatment Options in Wet AMD

Justus G. Garweg, MD

Switching to a New Anti-VEGF Agent Early in the Course of Therapy

Seenu M. Hariprasad, MD

Extending Duration in a Patient With Polypoidal Choroidal Vasculopathy

Peter Kertes, MD, FRCS(C)

Managing a Patient With High Treatment Burden and a History of Intraocular Inflammation

Arshad M. Khanani, MD, MA

Interactive Supplements

The Art of Drug Choice

View Resource

Listen as a Podcast

New Retina Radio

All video episodes of this series are also available as podcast episodes on New Retina Radio.

Listen Now

About This Editorial Feature

Arshad M. Khanani, MD, MA, moderates discussions with retina specialists from around the world, addressing the modern challenges of wet AMD management. Dr. Khanani and the participants address questions of real-world safety, summarize late-phase and early-phase clinical trial data, and share cases of challenging patients.